Intellia Therapeutics

NTLANasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$1.712 B

$12.22 +0.66%

Close of 21 Sept 2026

Revenue

$67.7M

#2633 by revenue

Earnings

-$412.7M

Loss-making

Shares outstanding

140,126,693

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#4Celldex TherapeuticsCLDX$2.98B
#5NeogenNEOG$2.97B
#6Intellia TherapeuticsNTLA$1.71B
#7Achieve Life SciencesACHV$828.4M
#8Anbio BiotechnologyNNNN$817.3M

What if Intellia Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$216,047.73

Per share 17,680× higher

Bitcoin $1.72T

$12,273.21

Per share 1,004× higher

Nvidia $5.48T

$39,106.45

Per share 3,200× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Intellia Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.